Page 37 - Read Online
P. 37

Page 10 of 14                                             Irshad et al. Hepatoma Res 2018;4:23  I  http://dx.doi.org/10.20517/2394-5079.2018.25

               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2018.



               REFERENCES
               1.   Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-
                   specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
               2.   Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41.
               3.   Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29 Suppl 1:74-81.
               4.   McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005;11:S286-95; quiz S307-11.
               5.   Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol
                   2017;9:1305-14.
               6.   Chevaliez S, Pawlotsky JM. HCV Genome and Life Cycle. In: Tan SL, editor. Hepatitis C Viruses: Genomes and Molecular Biology.
                   UK: Norfolk; 2006.
               7.   Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV core region: important predictors of HCV induced pathogenesis and viral
                   production. Infect Genet Evol 2011;11:543-56.
               8.   Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett
                   2003;546:385-90.
               9.   Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and
                   release of infectious virions. PLoS Pathog 2007;3:e103.
               10.  Steinmann E, Pietschmann T. Hepatitis C virus p7-a viroporin crucial for virus assembly and an emerging target for antiviral therapy.
                   Viruses 2010;2:2078-95.
               11.  Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkühler C, De Francesco R. Multiple enzymatic activities associated with
                   recombinant NS3 protein of hepatitis C virus. J Virol 1998;72:6758-69.
               12.  Stapleford KA, Lindenbach BD. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2
                   glycoprotein and NS3- NS4A enzyme complexes. J Virol 2011;85:1706-17.
               13.  Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour A. Nonstructural protein 3-4A: the Swiss army knife of
                   hepatitis C virus. J Viral Hepat 2011;18:305-15.
               14.  Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B:a journey into unexplored territory. Rev Med Virol
                   2010;20:117-29.
               15.  Macdonald A, Crowder K, Street A, McCormick C, Harris M. The hepatitis C virus NS5A protein binds to members of the Src family of
                   tyrosine kinases and regulates kinase activity. J Gen Virol 2004;85:721-9.
               16.  Reed KE, Xu J, Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated
                   kinase. J Virol 1997;71:7187-97.
               17.  Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63.
               18.  Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Disease. Diagnosis, management, and
                   treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
               19.  Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are
                   cost-saving. Clin Gastroenterol Hepatol 2017;15:827-37.e8.
               20.  Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012;32:9-16.
               21.  Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct acting antivirals. Hepatology 2013;58:428-38.
               22.  Temesgen Z, Rizza SA. Daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc) 2015;51:277-88.
               23.  Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson
                   JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with
                   pegylated interferon alfa-2a and ribavirin for treatment- naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label,
                   randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7.
               24.  Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson
                   DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH,
                   Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. Sofosbuvir in combination with
                   peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a
                   randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8.
               25.  Issur M, Gotte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses
   32   33   34   35   36   37   38   39   40   41   42